The Effect of Bicarbonate Administration via Continuous Venovenous Hemofiltration on Acid-Base Parameters in Ventilated Patients

Table 4

Continuous venovenous hemofiltration prescription characteristics.

	All subjects; ()	Bicarbonate; 4K^+/2.5Ca^++; ()	Bicarbonate; 2K^+/0Ca^++; ()	Bicarbonate; 0K^+/2.5Ca^++; ()	Citrate; ()
Blood flow rate (mL/min)
Mean ± SD	238 ± 33	238 ± 34	244 ± 17	247 ± 11	175 ± 46
Median [25th, 75th]	250 250, 250]	250 250, 250]	250 250, 250]	250 250, 250]	150 150, 200]
(min, max)	(150, 250)	(150, 250)	(200, 250)	(200, 250)	(150, 250)
Solution flow rate (mL/h)
Mean ± SD	2214 ± 484	2158 ± 462	2220 ± 527	2563 ± 453	2050 ± 256
Median [25th, 75th]	2000 2000, 2400]	2000 2000, 2400]	2000 2000, 2400]	2500 2000, 3000]	2000 2000, 2200]
(min, max)	(2000, 3200)	(2000, 3200)	(2000, 3000)	(2000, 3000)	(1600, 2400)
Ultrafiltration rate (mL/h)
Mean ± SD	45 ± 62	47 ± 63	39 ± 51	45 ± 53	50 ± 53
Median [25th, 75th]	0 0, 100]	10 0, 100]	0 0, 100]	0 0, 50]	50 0, 100]
(min, max)	(0, 250)	(0, 250)	(0, 150)	(0, 250)	(0, 100)

Rates reflect average values over the course of the 96-hour study duration. represents the number of subjects on a given solution prescription at the time of CVVH initiation.